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Mesoporous Silica Nanoparticle-Based Double Drug Delivery System for
Glucose-Responsive Controlled Release of Insulin and Cyclic AMP
Abstract
A boronic acid-functionalized mesoporous silica nanoparticle-based drug delivery system (BA-MSN) for
glucose-responsive controlled release of both insulin and cyclic adenosine monophosphate (cAMP) was
synthesized. Fluorescein isothiocyanate-labeled, gluconic acid-modified insulin (FITC-G-Ins) proteins were
immobilized on the exterior surface of BA-MSN and also served as caps to encapsulate cAMP molecules
inside the mesopores of BA-MSN. The release of both G-Ins and cAMP was triggered by the introduction of
saccharides. The selectivity of FITC-G-Ins release toward a series of carbohydrate triggers was determined to
be fructose > glucose > other saccharides. The unique feature of this double-release system is that the decrease
of FITC-G-Ins release with cycles can be balanced by the release of cAMP from mesopores of MSN, which is
regulated by the gatekeeper effect of FITC-G-Ins. In vitro controlled release of cAMP was studied at two pH
conditions (pH 7.4 and 8.5). Furthermore, the cytotoxicity of cAMP-loaded G-Ins-MSN with four different
cell lines was investigated by cell viability and proliferation studies. The cellular uptake properties of cAMP-
loaded FITC-BA-MSN with and without G-Ins capping were investigated by flow cytometry and fluorescence
confocal microscopy. We envision that this glucose-responsive MSN-based double-release system could lead
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Stimuli-responsive controlled-release systems have attracted
much attention for their potential applications in the area of drug
and gene delivery.1-3 In particular, surface-functionalized, end-
capped mesoporous silica nanoparticle (MSN) materials have been
demonstrated as efficient stimuli-responsive controlled-release
systems having the advantageous “zero premature release” property.
The biocompatibility of MSN both in vitro and in vivo has been
demonstrated by several recent studies.4-7 Furthermore, literature
reports on the biodistribution and circulation properties of MSN
administered in animals by intravenous injection have highlighted
the promising potential of these multifunctional nanoparticles for
in vivo biomedical applications and organ-specific delivery of
therapeutics.
In contrast to nonporous nanoparticles, MSN offers both interior
pore and exterior particle surfaces for loading different guest
molecules. This is particularly useful for controlling the sequence
of release for different cargos, which is crucial for the efficacy of
many codelivery applications. These codelivery systems with control
over the sequence of release could play a key role in overcoming
several current challenges in therapy. For example, conventional
glucose-responsive insulin delivery systems suffer from the decrease
of insulin release with repeated cycles.8,9 This problem could
be overcome if the secretion of insulin from live cells could also
be induced by sequential delivery of cyclic adenosine monophos-
phate (cAMP), which activates Ca2+ channels of pancreas beta cells
and hence stimulates insulin secretion.10,11 However, because of
the poor membrane permeability of cAMP, many attempts have
been made to develop cAMP analogues12 with good membrane
permeability to study the insulin secretion mechanism. Unfortu-
nately, to the best of our knowledge, no report of intracellular cAMP
delivery by any drug carriers to control insulin production has
appeared in the literature.
Herein, we report on the synthesis of a glucose-responsive MSN-
based double delivery system for both insulin and cAMP with
precise control over the sequence of release. As depicted in Figure
1a, gluconic acid-modified insulin (G-Ins)8 proteins are immobilized
on the exterior surface of MSN and also serve as caps to encapsulate
cAMP molecules inside the mesopores of MSN. The release of
both G-Ins and cAMP from MSN can be triggered by the
introduction of saccharides, such as glucose. Also, we have
demonstrated that the uncapped MSN can be efficiently endocytosed
by live mammalian cells, leading to effective intracellular release
of the cell-membrane-impermeable cAMP.
We first synthesized an aminopropyl-functionalized (1.6 mmol
g-1) mesoporous silica nanosphere material (AP-MSN) with an
average particle diameter of 120 nm and an MCM-41-type channel-
like mesoporous structure (BJH pore diameter ) 2.3 nm) via a
method that we previously reported.13 The particle size is small
enough (e200 nm) to evade rapid sequestration by phagocytotic
cells of the spleen and to allow long blood circulation.14 As
described in the Supporting Information (SI), 4-carboxyphenylbo-
ronic acid (0.15 g), N-hydroxysuccinimide (0.10 g), and 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.2 g) were
introduced to AP-MSN (400 mg) in DMSO (20 mL) to yield the
boronic acid-functionalized (0.5 mmol g-1) MSN material (BA-
MSN) (Figure 1b). The presence of both aminopropyl and phenyl-
boronic acid groups stabilizes the formation of borates with 1,2-
or 1,3-diols (Figure 1a). A fluorescein isothiocyanate (FITC)-labeled
G-Ins (FITC-G-Ins) was prepared according to a literature proce-
dure.8 The bioactivity of G-Ins was demonstrated to be similar to
that of unmodified insulin.8 The mesopores of BA-MSN (100 mg)
were loaded with cAMP (1 mM) in PBS buffer (10 mL, pH 7.4)
and then capped with FITC-G-Ins (200 mg) through reversible
covalent bonding between phenylboronic acid and the vicinal diols
of FITC-G-Ins, giving rise to the desired FITC-G-Ins-MSN material
(Figure 1c). The loadings of cAMP and FITC-G-Ins were deter-
mined to be 27 and 64 µmol/g by HPLC15 and fluorescence
emission spectroscopy, respectively. As detailed in the SI, the
structures and surface properties of BA-MSN and FITC-G-Ins-MSN
Figure 1. (a) Schematic representation of the glucose-responsive MSN-
based delivery system for controlled release of bioactive G-Ins and cAMP.
Transmission electron micrographs of (b) boronic acid-functionalized MSN
and (c) FITC-G-Ins-capped MSN.
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were characterized by powder X-ray diffraction (XRD), N2 surface
analysis,  potential measurements, and transmission electron
microscopy.
As demonstrated in the literature,16 phenylboronic acid forms
much more stable cyclic esters with the adjacent diols of saccharides
than with acyclic diols. This means that the linkage between FITC-
G-Ins and BA-MSN could be cleaved by introducing various
saccharides. Therefore, it was expected that the release of FITC-
G-Ins would be sensitive to the chemical structures and concentra-
tions of different carbohydrate triggers in forming stable cyclic
boronic esters with BA-MSN. Among different saccharide triggers,
the release of FITC-G-Ins indeed showed a strong preference for
fructose, followed by glucose, as shown in Figure 2a. The observed
high selectivity for fructose is consistent with other reported
monoboronic acid-based sensors for saccharide recognition.17 It is
known that saccharides can interconvert between their pyranose
and furanose isomeric forms, and phenylboronic acid has a strong
preference for binding with the hydroxyls of saccharides in their
furanose forms. The high selectivity toward fructose could be
explained by its high percentage of furanose form in water (25%
for fructose vs 0.14% for glucose).18
For monoboronic acids in water with 1:1 saccharide/boronic acid
complexation, high selectivity for fructose and low selectivity for
glucose were observed, and the difference was attributed to the
relative percentage of the furanose forms of these carbohydrates.18
Interestingly, our system was highly responsive toward fructose
and glucose in comparison with other saccharides (Figure 2a). This
could be attributed to the heterogeneous spacing of boronic acid
groups, which leads to the coexistence of 1:1 and 1:2 complexation,
where the 1:2 complexation is widely used in the design of
diboronic acid systems for selective glucose sensing.19 In contrast,
disaccharides (lactose and maltose) were not able to adopt a
furanose form and hence could not serve as effective triggers for
pore uncapping. While a stronger preference for fructose than for
glucose was observed, the FITC-G-Ins-MSN system is still suitable
for glucose-responsive insulin release because of the much lower
level of blood fructose (e0.1 mM) than of glucose (g10 mM) in
diabetic patients.
The release of FITC-G-Ins triggered by any of the saccharides
was found to be complete within 30 min, which is within the time
frame of normal insulin secretion. The complexation of fructose
and glucose with phenylboronic acid and the corresponding release
of FITC-G-Ins exhibited a strong pH dependence. As shown in
Figure 2b, the release of FITC-G-Ins triggered by 50 mM fructose
reached 85% of maximum release at pH 7.4. In contrast, significant
release of FITC-G-Ins was observed only at pH values above 8 in
the case of glucose. This is likely due to the fact that the formation
of tetrahedral borate intermediate requires a pH higher than the
pKa of boronic acid. The observed pH dependence in our material,
which is indicative of the controlled release mechanism, is consistent
with those of other literature-reported insulin delivery systems.20
To further examine the applicability of this system, FITC-G-Ins
released by a stepwise treatment of glucose at two diabetic levels
(50 and 100 mM) was monitored (Figure S6 in the SI). A typical
decrease in insulin release after the second cycle was observed.
However, this problem of decreasing insulin level could be
overcome by delivering the cell-membrane-impermeable cAMP into
the cytosol to stimulate insulin secretion from pancreas beta cells.
This double-release system sets up a new model for self-regulated
insulin-releasing devices.
The glucose-triggered release of cAMP by FITC-G-Ins uncapping
was determined by HPLC15 at pH 7.4 and 8.5, as shown in Figure
3. In PBS (pH 7.4), the cAMP-loaded FITC-G-Ins-MSN exhibited
less than 10% leaching in the absence of glucose trigger, suggesting
a good capping efficiency of FITC-G-Ins. The rate of cAMP release
triggered by 50 mM glucose at pH 7.4 and 8.5 showed similar
diffusion-controlled kinetic profiles. Specifically, ∼80% of total
release was obtained within 20 h. Furthermore, 55 and 67% of the
total loaded cAMP (27 µmol g-1) were released after 30 h at pH
7.4 and 8.5, respectively (Figure 3a). As shown in Figure 3b, the
release of cAMP strongly depends on the concentration of glucose.
A significant cAMP release at pH 7.4 was observed when the
concentration of glucose trigger was above 100 mM, whereas 50
mM glucose triggered almost 60% of maximum release at pH 8.5.
This pH dependence of cAMP release is consistent with that of
FITC-G-Ins release from MSN.
To correlate these in vitro results with the physiological
concentrations for potential in vivo applications, the therapeutic
dosage of this material was estimated. Between meals, the insulin
level typically rises from a fasting level of 20-30 pM to a 30 min
maximum of 250-300 pM, depending upon the amount and quality
of carbohydrates consumed, while the diabetic insulin level remains
at 20-30 pM or below. It has been reported in the literature that
at least 250-300 pM of insulin is needed to decrease the diabetic
blood glucose concentration to the normal level.21 Our results
indicate that 20 mM glucose indeed induced the release of 2 µM
G-Ins from our material at a concentration of 2 mg mL-1 (Figure
2a). Delivery of 250-300 pM of G-Ins would require only 0.25-0.3
µg mL-1 MSN material, which is 4 orders of magnitude lower in
concentration than what we have demonstrated above. As reported
previously, the MSN dosage has a minimal effect on viability and
proliferation of mammalian cells at concentrations below 100 µg
mL-1 after 6 days.22 Also, the maximum concentration of cAMP
released from 2 mg mL-1 G-Ins-MSN was 30 µg mL-1 (Figure
3b). On the basis of these results, we envision that the application
of 0.25-0.30 µg mL-1 G-Ins-MSN in vivo could sufficiently deliver
Figure 2. (a) Dependence of FITC-G-Ins release from FITC-G-Ins-MSN
(2 mg mL-1 in PBS, pH 7.4) on the concentration of saccharide triggers.
(b) pH titration of insulin release from FITC-G-Ins-MSN (2 mg mL-1 in
PBS) triggered by 50 mM glucose (solid line) and 50 mM fructose (dashed
line).
Figure 3. Controlled release of cAMP from FITC-G-Ins-MSN (2 mg mL-1
in PBS) (a) triggered by 50 mM glucose at pH 7.4 (b) and 8.5 (2), with
control data at pH 7.4 in the absence of glucose (9), and (b) triggered by
different concentrations of glucose at pH 7.4 (solid line) and 8.5 (dashed
line) measured 48 h after glucose treatment.
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both G-Ins and cAMP for blood glucose regulation and insulin
secretion, respectively, and would not produce any acute toxic
effects.
To examine the cytotoxicity of the cAMP-loaded G-Ins-MSN
material, cell viability and proliferation profiles of four different
cell lines [rat pancreatic islet tumor (RIN-5F), mouse liver, skin
fibroblast, and human cervical cancer (HeLa) cells] were evaluated
by Guava ViaCount cytometry assay after 24 h inoculation with
the material. Good cell viability (>90%) and proliferation (>80%)
were observed for all cell lines containing 5 or 20 µg mL-1 G-Ins-
MSN. These results further indicate that this MSN-based double
delivery system is biocompatible.
The cellular uptake properties of the cAMP-loaded BA-MSN
with and without G-Ins capping were investigated with RIN-5F cells.
As detailed in the SI, BA-MSN labeled with FITC (FITC-BA-MSN)
for this study was prepared prior to cAMP loading and G-Ins
capping. The endocytosis efficiency was quantified by flow cy-
tometry after 1 h of incubation with each material at 10 µg mL-1
(Figure S8). Interestingly, the cAMP-loaded FITC-BA-MSN with-
out G-Ins capping showed a 2-fold higher endocytosis efficiency
than that of the G-Ins-capped material. The result could be attributed
to the difference in their surface charge properties: the  potentials
were -28.3 mV for the uncapped material and -44.5 mV for the
G-Ins-capped version.13 This difference between the endocytosis
efficiencies of the capped and uncapped materials implies that
G-Ins-MSN could circulate in the regulatory system before the
glucose-induced G-Ins release, and the enhanced cellular uptake
of cAMP-loaded BA-MSN after the pore uncapping would allow
efficient intracellular cAMP delivery.
To quantify the degree of intracellular release of cAMP from
our system, the cAMP-loaded BA-MSN was allowed to be
internalized by RIN-5F cells. After 6 h of incubation, the total
cellular concentration of cAMP was measured using a Millipore
cAMP HTS immunoassay (see the SI). The result was compared
with that of RIN-5F cells introduced to free-solution cAMP. As
shown in Figure 4a, the total cellular concentration of cAMP indeed
increased proportional to the dosage of cAMP-loaded BA-MSN.
In contrast, no significant elevation of the cellular concentration of
cAMP was observed in the case of free-solution cAMP, even at
the high dosage of 20 µg mL-1, which is consistent with the poor
cell-membrane permeability of free-solution cAMP.
To visualize intracellular delivery of cAMP, a membrane
impermeable, fluorescence-labeled cAMP (8-Fluo-cAMP)23 was
loaded into the BA-MSN. Fluo-cAMP-loaded BA-MSN (20 µg
mL-1) was incubated with RIN-5F cells for 6 h. The fluorescence
confocal micrographs (Figure 4b-d) clearly showed that Fluo-
cAMP-loaded BA-MSN was indeed internalized by live RIN-5F
cells. Green fluorescence was observed for both Fluo-cAMP-loaded
BA-MSN particles and the free Fluo-cAMP molecules released from
the MSN intracellularly.
In conclusion, we have successfully demonstrated that phenyl-
boronic acid-functionalized MSN can serve as an efficient code-
livery system for saccharide-responsive controlled release of insulin
and cAMP. The good biocompatibility, cellular uptake properties,
and efficient intracellular release of cAMP set up the basis for future
in vivo controlled-release biomedical applications.
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Figure 4. (a) Intracellular cAMP concentration of rat pancreatic RIN-5F
cells treated with the cAMP-loaded BA-MSN (solid line) and free-solution
cAMP (dashed line), measured after 6 h of introduction. (b) Fluorescence
confocal micrograph of RIN-5F cells incubated with 20 µg mL-1 Fluo-
cAMP-loaded BA-MSN (green) for 6 h. Cell nuclei were stained with DAPI
(blue). (c) Corresponding differential interference contrast (DIC) micro-
graphs. (d) Fluorescence confocal and DIC merged image. Enlarged
individual and merged images are shown in Figure S9 in the SI.
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